WO2020013058A1 - Rnaからの核酸増幅反応に適したdnaポリメラーゼ変異体 - Google Patents
Rnaからの核酸増幅反応に適したdnaポリメラーゼ変異体 Download PDFInfo
- Publication number
- WO2020013058A1 WO2020013058A1 PCT/JP2019/026513 JP2019026513W WO2020013058A1 WO 2020013058 A1 WO2020013058 A1 WO 2020013058A1 JP 2019026513 W JP2019026513 W JP 2019026513W WO 2020013058 A1 WO2020013058 A1 WO 2020013058A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- acid residue
- dna polymerase
- mutant
- reverse transcriptase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07007—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
Definitions
- the present invention relates to a DNA polymerase mutant suitable for a nucleic acid amplification reaction from RNA. Furthermore, the present invention relates to a method for improving the activity of amplifying a nucleic acid from an existing DNA polymerase, and a method for producing a mutant DNA polymerase suitable for a nucleic acid amplification reaction from the RNA.
- DNA polymerase plays a central role in the accurate transmission of genetic information from generation to generation, such as replication and retention of the genome.
- DNA polymerases function intracellularly as enzymes responsible for the synthesis of DNA.
- Deoxyribonucleoside triphosphates are present in the presence of metal activators such as Mg 2+ in the order required for replication of template DNA or template polynucleotide. Is polymerized.
- DNA polymerase is involved in a series of DNA synthesis processes including DNA replication, DNA repair, recombination and gene amplification. During each DNA synthesis step, the template DNA is replicated once or several times to produce identical duplicates.
- DNA replication can be repeated many times, for example, as in the polymerase chain reaction.
- RT-PCR reverse transcription polymerase chain reaction
- a one-step RT-PCR method has been developed in which the reverse transcription reaction and PCR are performed continuously without opening the reaction vessel.
- a DNA polymerase having a reverse transcriptase activity may be used.
- the reverse transcription reaction and the PCR are performed with the same reaction solution composition, it is essential to balance the reverse transcription reaction and the PCR.
- techniques for improving the reverse transcription efficiency when the reverse transcription reaction and the PCR have the same reaction solution composition have been reported. (See Patent Documents 1 to 3).
- An object of the present invention is to provide an improved genetic engineering method for creating a DNA polymerase having a reverse transcriptase activity suitable for performing a reverse transcription reaction and a nucleic acid amplification reaction in the same container.
- the present inventors have conducted intensive studies to develop a DNA polymerase mutant having a reverse transcriptase activity suitable for performing a reverse transcription reaction and a nucleic acid amplification reaction.
- the present inventors have succeeded in finding a method for producing a DNA polymerase mutant having a reverse transcriptase activity superior to that of the prior art, and completed the present invention.
- a first invention of the present invention is a mutant of a DNA polymerase having a reverse transcriptase activity, comprising a sequence consisting of 12 amino acids A1 to A12, wherein A1 is a branched-chain amino acid residue.
- A2 is a hydrophilic neutral amino acid residue or a hydrophobic aliphatic amino acid residue
- A3 is a hydrophilic neutral amino acid residue
- A4 is an acidic amino acid residue or a hydrophilic neutral amino acid residue
- A5 is a branched amino acid residue
- A6 is a hydrophobic aliphatic amino acid residue or a hydrophilic neutral amino acid residue
- A7 is a branched-chain amino acid residue
- A8 is a proline residue or a hydrophilic neutral amino acid residue
- A9 is a hydrophobic aromatic amino acid residue, a basic amino acid residue or a hydrophilic neutral amino acid residue
- A10 is an acidic amino acid residue or a basic amino acid residue
- A11 is an acidic amino acid residue
- A12 is a hydrophobic aliphatic amino acid residue
- the amino acid of A3 and / or A10 has been substituted with another basic amino acid residue different from that before mutation.
- mutant DNA polymerase having reverse transcriptase activity wherein A1 is leucine, A3 is glutamine, A5 is leucine, A7 is isoleucine, and A11 is Those in which glutamic acid and A12 are alanine are preferred.
- the amino acid of A3 and / or A10 in the sequence of 12 amino acids is selected from the group consisting of lysine, arginine and histidine. What is substituted by is preferable. Although not particularly limited, substitution with arginine is preferred.
- the mutant DNA polymerase having a reverse transcriptase activity of the first invention of the present invention is particularly preferably derived from a DNA polymerase having a reverse transcriptase activity suitable for performing a reverse transcription reaction and a nucleic acid amplification reaction in the same container.
- a DNA polymerase derived from Thermus thermophilus a DNA polymerase derived from Thermus aquaticus, a DNA polymerase derived from Bacillus cardotenax, a DNA polymerase derived from Bacillus stearothermophilus, or a DNA derived from Alicyclobacillus acid Caldarius Polymerase variants are preferred.
- the second invention of the present invention relates to a kit comprising the DNA polymerase mutant having a reverse transcriptase activity of the first invention of the present invention.
- the kit may include various components as a kit for preparing a reaction solution suitable for a reverse transcription reaction and a nucleic acid amplification reaction described below.
- the third invention of the present invention relates to a composition comprising the DNA polymerase mutant having a reverse transcriptase activity of the first invention of the present invention.
- the composition may contain various components as a composition suitable for a reverse transcription reaction and a nucleic acid amplification reaction described below.
- the fourth invention of the present invention is a method for producing a DNA polymerase having a reverse transcriptase activity suitable for nucleic acid amplification from RNA, (1) selecting a DNA polymerase comprising a sequence consisting of the following 12 amino acids A1 to A12; A1 is a branched amino acid residue; A2 is a hydrophilic neutral amino acid residue or a hydrophobic aliphatic amino acid residue; A3 is a hydrophilic neutral amino acid residue; A4 is an acidic amino acid residue or a hydrophilic neutral amino acid residue; A5 is a branched amino acid residue; A6 is a hydrophobic aliphatic amino acid residue or a hydrophilic neutral amino acid residue, A7 is a branched-chain amino acid residue; A8 is a proline residue or a hydrophilic neutral amino acid residue; A9 is a hydrophobic aromatic amino acid residue, a basic amino acid residue or a hydrophilic neutral amino acid residue; A10 is an acidic amino acid residue or a basic amino
- step (1) in the sequence consisting of the 12 amino acids in the step (1), A1 is leucine, A3 is glutamine, A5 is leucine, A7 is isoleucine, A11 is glutamic acid and A12 is alanine. It may be a step of selecting a DNA polymerase. Further, step (2) may be a step in which A3 and / or A10 are substituted with an amino acid selected from the group consisting of lysine, arginine and histidine.
- the production method of the fourth invention of the present invention may be combined with a method of preparing a nucleic acid encoding the mutant and introducing the nucleic acid into an appropriate host to express the mutant.
- the fifth invention of the present invention relates to a method for improving a DNA polymerase having a reverse transcriptase activity, which comprises a DNA polymerase having a reverse transcriptase activity and comprising a sequence consisting of 12 amino acids represented by the following A1 to A12: And / or substituting the amino acid of A10 with another basic amino acid residue:
- A1 is a branched amino acid residue;
- A2 is a hydrophilic neutral amino acid residue or a hydrophobic aliphatic amino acid residue;
- A3 is a hydrophilic neutral amino acid residue;
- A4 is an acidic amino acid residue or a hydrophilic neutral amino acid residue;
- A5 is a branched amino acid residue;
- A6 is a hydrophobic aliphatic amino acid residue or a hydrophilic neutral amino acid residue, A7 is a branched-chain amino acid residue;
- A8 is a proline residue or a hydrophilic neutral amino acid residue;
- A9 is a hydropho
- the DNA polymerase having a reverse transcriptase activity may be, for example, A1 is leucine, A3 is glutamine, A5 is leucine, A7 is isoleucine, and A11 is A DNA polymerase in which glutamic acid and A12 are alanine can be selected.
- A3 and / or A10 in the sequence consisting of 12 amino acids can be replaced with, for example, an amino acid selected from the group consisting of lysine, arginine and histidine.
- a DNA polymerase having a reverse transcriptase activity comprising a sequence consisting of 12 amino acids A1 to A12, A1 is leucine; A2 is serine or alanine; A3 is glutamine; A4 is glutamic acid or asparagine; A5 is leucine; A6 is alanine or asparagine; A7 is isoleucine; A8 is proline, serine or threonine; A9 is tyrosine, arginine or glutamine; A10 is glutamic acid or lysine; A11 is glutamic acid; A12 is preferably an alanine; and a mutant in which the amino acid of A3 and / or A10 has been substituted with another basic amino acid residue different from that before mutagenesis. For example, the amino acid of A3 and / or A10 is lysine. Or a mutant of DNA polymerase substituted with an amino acid selected from the group consisting of
- a DNA polymerase mutant having a reverse transcriptase activity suitable for performing a reverse transcription reaction and a nucleic acid amplification reaction in the same container and a method for producing the same are provided.
- the DNA polymerase having the reverse transcriptase activity having the specific amino acid sequence site represented by A1 to A12 can carry out the mutation introduction of the present invention, and as a result, the DNA polymerase is more reversely mutated than before.
- the transcription reaction time can be shortened, and a sufficient quantity can be generated as the initial template amount for the subsequent nucleic acid amplification reaction, and the reverse transcriptase reaction and the nucleic acid amplification reaction can achieve higher detection sensitivity in a shorter time than before. it can.
- the DNA polymerase mutant having reverse transcriptase activity of the present invention relates to a DNA polymerase mutant suitable for a reverse transcriptase reaction and a nucleic acid amplification reaction.
- the mutant of the present invention is a mutant of a DNA polymerase having reverse transcriptase activity, comprising a sequence consisting of 12 amino acids A1 to A12, wherein A1 is a branched-chain amino acid residue; A2 is a hydrophilic neutral amino acid residue or a hydrophobic aliphatic amino acid residue; A3 is a hydrophilic neutral amino acid residue; A4 is an acidic amino acid residue or a hydrophilic neutral amino acid residue; A5 is a branched amino acid residue; A6 is a hydrophobic aliphatic amino acid residue or a hydrophilic neutral amino acid residue, A7 is a branched-chain amino acid residue; A8 is a proline residue or a hydrophilic neutral amino acid residue; A9 is a hydrophobic aromatic amino
- the mutant having the above structure is a DNA polymerase mutant suitable for a reverse transcription reaction and a nucleic acid amplification reaction performed in one container.
- the “branched amino acid residue” is exemplified by a valine residue, an isoleucine residue or a leucine residue.
- the “hydrophilic neutral amino acid residue” is exemplified by a serine residue, a threonine residue, an asparagine residue or a glutamine residue.
- the “hydrophobic aliphatic amino acid residue” is exemplified by a glycine residue or an alanine residue.
- the “acidic amino acid residue” is exemplified by an aspartic acid residue or a glutamic acid residue.
- hydrophobic aromatic amino acid residue is exemplified by a phenylalanine residue, a tyrosine residue or a tryptophan residue.
- basic amino acid residue is exemplified by a lysine residue, an arginine residue or a histidine residue.
- A1 is leucine
- A3 is glutamine
- A5 is leucine
- A7 isoleucine
- A11 is glutamic acid
- A12 is alanine.
- a DNA polymerase having transcriptase activity can be used as a material for the mutant.
- a preferred example of the mutant of the present invention is a DNA polymerase comprising a sequence consisting of the above 12 amino acids A1 to A12 and having a reverse transcriptase activity, wherein the amino acid A3 and / or A10 is selected from lysine, arginine and histidine.
- a variant substituted with an amino acid selected from the group consisting of: Particularly preferred is a mutant substituted with arginine.
- a DNA polymerase having a reverse transcriptase activity comprising a sequence consisting of 12 amino acids A1 to A12, A1 is leucine; A2 is serine or alanine; A3 is glutamine; A4 is glutamic acid or asparagine; A5 is leucine; A6 is alanine or asparagine; A7 is isoleucine; A8 is proline, serine or threonine; A9 is tyrosine, arginine or glutamine; A10 is glutamic acid or lysine; A11 is glutamic acid; A12 is alanine; and a mutant in which the amino acid of A3 and / or A10 is substituted with another basic amino acid residue different from that before mutation is introduced.
- the amino acid of A3 and / or A10 is It may be a mutant of a DNA polymerase substituted with an amino acid selected from the group consisting of lysine, arginine and histidine.
- the amino acid sequence from position 680 to position 691 in SEQ ID NO: 1 of the polymerase corresponds to A1 to A12, and Specifically, it is the amino acid sequence of “LSQELAIPYEEA” (SEQ ID NO: 18). Accordingly, the glutamine residue at A3 (position 682) and / or the glutamic acid residue at A10 (position 689) of the Thermus thermophilus-derived DNA polymerase is replaced with an amino acid selected from the group consisting of lysine, arginine and histidine, preferably arginine.
- a mutant obtained by substitution mutation is exemplified as the mutant of the present invention.
- a mutant of the Thermus thermophilus-derived DNA polymerase having "LSRELAIPYREA" (SEQ ID NO: 19) can be suitably used as a DNA polymerase mutant suitable for a reverse transcriptase reaction and a nucleic acid amplification reaction.
- the mutant b13b46 of the DNA polymerase derived from Thermus thermophilus prepared in Example 1 of the present specification is a mutant having the above-mentioned Q682R and E689R.
- Similar mutants can also be prepared using a DNA polymerase having a reverse transcriptase activity derived from Thermus aquaticus, Bacillus cardotenax, Bacillus stearothermophilus or Alicyclobacillus acid cardarius. .
- a DNA polymerase having reverse transcriptase activity derived from Bacillus cardotenax has a sequence of “LAQNLNISRKEA” (SEQ ID NO: 20) as a 12 amino acid sequence consisting of A1 to A12. ing.
- the 12 amino acid sequence of a DNA polymerase having reverse transcriptase activity derived from Bacillus stearothermophilus is "LAQNLNITRKEA” (SEQ ID NO: 21).
- the 12 amino acid sequence of the DNA polymerase having a reverse transcriptase activity derived from Alicyclobacillus acid Caldarius is "LAQNLNIPQKEA" (SEQ ID NO: 22).
- the 12 amino acid sequence of the DNA polymerase having reverse transcriptase activity derived from Thermus aquaticus is "LSQELAIPYEEEA" (positions 678 to 689 of SEQ ID NO: 25).
- LSQELAIPYEEEA positions 678 to 689 of SEQ ID NO: 25.
- A3 and / or A10 in these amino acid sequences have been substituted with basic amino acid residues are exemplified as the mutants of the present invention.
- a mutant in which the amino acid of A3 and / or A10 is substituted with an amino acid selected from the group consisting of lysine, arginine and histidine.
- Particularly preferred is a mutant substituted with arginine.
- thermostable polymerase derived from a thermophilic bacterium, or a mesophilic DNA polymerase suitable for an isothermal nucleic acid amplification method in which a similar mutation is introduced are also included in the DNA polymerase mutant of the present invention. That is, Pol I type or Family A type DNA polymerase can also be suitably used as a target for the mutagenesis of the present invention.
- the DNA polymerase mutant of the present invention may be a combination of mutations introduced into sites other than the 12 amino acid sequences shown in A1 to A12 as long as the reverse transcriptase activity and the nucleic acid amplification activity are not impaired.
- the amino acid sequence of a DNA polymerase having a reverse transcriptase activity before mutagenesis for example, a DNA polymerase having a reverse transcriptase activity derived from Thermus thermophilus (NCBI ⁇ Reference ⁇ Sequence ⁇ WP_01122845.1) or Thermus Acqua
- Thermus Acqua With respect to the amino acid sequence of a DNA polymerase having a reverse transcriptase activity derived from Atticus (Genbank @ Acc. No.
- a DNA polymerase having a reverse transcriptase activity derived from Bacillus cardotenax (NCBI ⁇ Reference ⁇ Sequence ⁇ WP_047758145.1) and a reverse transcriptase activity derived from Bacillus stearothermophilus
- a DNA polymerase (Genbank @ Acc. @ No. AAA855558.1) or a DNA polymerase having a reverse transcriptase activity derived from Alicyclobacillus acid Caldarius (Genbank @ Acc. @ No.BAF33373.1)
- the 12 amino acids A1 to A12 described above are used.
- DNA polymerase mutant having reverse transcriptase activity of the present invention may be a mutant further lacking exonuclease activity.
- DNA polymerases derived from Thermus thermophilus, Thermus aquaticus, Bacillus cardotenax, Bacillus stearothermophilus, Alicyclobacillus acid cardarius, etc. lack 5 ⁇ 3 exonuclease activity. Mutants are known.
- the mutant lacking the exonuclease activity lacks the 5 ⁇ 3 exonuclease domain located on the N-terminal side of DNA polymerase.
- the mutant of the present invention can be a mutant having no 5 ⁇ 3 exonuclease activity by deleting the 5 ⁇ 3 exonuclease domain.
- the DNA polymerase mutant having reverse transcriptase activity of the present invention can produce a target cDNA even under reverse transcription reaction conditions in which the DNA polymerase before mutation introduction cannot achieve reverse transcription.
- the reverse transcription reaction conditions include a reduction in reaction time and an increase in reaction temperature.
- the amount of the reverse transcription reaction product is increased as compared with the DNA polymerase before the introduction of the mutation.
- a reverse transcription reaction requiring about 30 minutes in a 60 ° C. reaction using a DNA polymerase having a reverse transcriptase activity derived from Thermus thermophilus was carried out using a mutant of the present invention prepared from the DNA polymerase.
- the mutant of the present invention can be expected to further improve in terms of resistance to an inhibitor during the reaction and affinity for a template nucleic acid, as compared with the existing DNA polymerase having a reverse transcriptase activity.
- reverse transcriptase activity can be significantly improved with respect to Pol I type or family A type DNA polymerase, which originally has low reverse transcriptase activity.
- DNA polymerase variants with reverse transcriptase activity suitable for performing can be created.
- the mutant of the present invention may be a fusion protein with a PIP box (PIP @ box: PCNA ⁇ interaction ⁇ protein ⁇ box).
- PCNA a protein that promotes DNA polymerase activity, can also promote the reverse transcriptase activity of a DNA polymerase having reverse transcriptase activity.
- the DNA polymerase mutant of the present invention in which the PIP box is fused can be produced by combining the technique described in International Publication WO2017 / 090687.
- composition of the present invention means a composition containing the DNA polymerase mutant having reverse transcriptase activity of the present invention.
- One embodiment of the composition of the present invention is a composition suitable for a reverse transcription reaction and a nucleic acid amplification reaction.
- components necessary for the reverse transcription reaction and the polymerase chain reaction (RT-PCR) for example, divalent metal salts, dNTPs , Buffer components, reducing agents, sterile water and the like.
- composition of the present invention may also contain appropriate primers when the RNA to be amplified / detected is known.
- a composition suitable for the reverse transcription reaction and the isothermal nucleic acid amplification reaction a composition containing the same components as described above is preferable, as long as the composition contains the components necessary for the reverse transcription reaction and the isothermal nucleic acid amplification reaction.
- the divalent metal ion constituting the divalent metal salt is not particularly limited, and examples thereof include a manganese ion and a magnesium ion. Suitable divalent metal ions and their concentrations for reverse transcriptase are known in the art.
- the divalent metal ion can be provided in the form of a salt, such as chloride, sulfate, or acetate.
- the concentration of the divalent metal ion in the composition of the present invention is preferably, for example, 0.5 to 20 mM.
- the dNTP at least one of dATP, dCTP, dGTP, dTTP, or a derivative thereof is used. Preferably, four mixtures of dATP, dCTP, dGTP and dTTP are used.
- the buffer component for maintaining the pH is not particularly limited, Tris buffer, Tricine buffer, Bicine buffer, HEPES buffer, acetate buffer or phosphate buffer may be used. Is exemplified.
- buffer components and their concentrations suitable for reverse transcription and nucleic acid amplification reactions are known in the art.
- the reducing agent for the reverse transcription reaction include, but are not particularly limited to, DTT (dithiothreitol) and 2-mercaptoethanol. Suitable reducing agents and their concentrations for reverse transcription reactions are known in the art.
- the chain length of the primer is preferably 6 nucleotides or more, more preferably 10 nucleotides or more, and preferably 100 nucleotides or less from the viewpoint of oligonucleotide synthesis. Preferably it is 30 nucleotides or less.
- a mixture of oligonucleotides having a chain length of 6 to 8 nucleotides may be used as random primers for the purpose of nonspecific cDNA synthesis.
- the oligonucleotide can be chemically synthesized, for example, by a known method.
- Oligonucleotides derived from biological samples may also be used. For example, they may be produced by isolation from restriction endonuclease digests of DNA prepared from natural samples.
- the nucleic acid amplification reaction it may include a primer pair designed according to the sequence of the nucleic acid to be amplified.
- the reverse transcription reaction primer may also serve as one of the nucleic acid amplification primers.
- the kit of the present invention is an RT-PCR kit or an RT-isothermal nucleic acid amplification kit suitable for a reverse transcription reaction and a nucleic acid amplification reaction method.
- the kit of the present invention includes: Contains DNA polymerase mutants, divalent metal salts, dNTPs, buffer components, reducing agents, and other components suitable for reverse transcription and nucleic acid amplification reactions suitable for the reverse transcription reaction and nucleic acid amplification reaction of the present invention described in A kit for preparing a reverse transcription reaction / nucleic acid amplification reaction solution by mixing them at the time of use, containing the above-described composition of the present invention, and only adding a template DNA and water (such as sterile water) at the time of use.
- a template DNA and water such as sterile water
- kits containing the composition of the present invention in a dry state A kit containing a primer specific to a target RNA and an RNA for a positive control for the purpose of detecting a specific RNA is also included in the present invention.
- the divalent metal salt, dNTPs, buffer component, and reducing agent are as described above.
- composition or kit of the present invention may further contain components necessary for detecting the amplified double-stranded nucleic acid, such as an intercalator and a fluorescently labeled probe.
- an intercalator and a fluorescently labeled probe.
- SYBR registered trademark
- Green I Green I
- TB Green registered trademark
- TaqMan registered trademark
- Cycleave registered trademark
- molecular beacon probes are used as fluorescent label probes. And the like.
- the method for producing a DNA polymerase mutant having a reverse transcriptase activity of the present invention The method for producing a DNA polymerase mutant suitable for a reverse transcriptase reaction and a nucleic acid amplification reaction according to the present invention is described in 1. above.
- the present invention relates to a method for producing a DNA polymerase mutant described in (1).
- a specific embodiment of the production method of the present invention is a method for producing a DNA polymerase having a reverse transcriptase activity suitable for nucleic acid amplification from RNA, (1) selecting a DNA polymerase comprising a sequence consisting of the following 12 amino acids A1 to A12; A1 is a branched amino acid residue; A2 is a hydrophilic neutral amino acid residue or a hydrophobic aliphatic amino acid residue; A3 is a hydrophilic neutral amino acid residue; A4 is an acidic amino acid residue or a hydrophilic neutral amino acid residue; A5 is a branched amino acid residue; A6 is a hydrophobic aliphatic amino acid residue or a hydrophilic neutral amino acid residue, A7 is a branched-chain amino acid residue; A8 is a proline residue or a hydrophilic neutral amino acid residue; A9 is a hydrophobic aromatic amino acid residue, a basic amino acid residue or a hydrophilic neutral amino acid residue; A10 is an acidic amino acid residue or
- a DNA polymerase comprising a 12 amino acid sequence comprising an amino acid sequence in which A1 is leucine, A3 is glutamine, A5 is leucine, A7 is isoleucine, A11 is glutamic acid and A12 is alanine is used as a material for mutagenesis. You can choose.
- the DNA polymerase having reverse transcriptase activity selected above is substituted with A3 and / or A10 by an amino acid selected from the group consisting of lysine, arginine and histidine. Is preferred. Particularly preferably, it is substituted with arginine.
- Step (1) can be carried out by extracting a DNA polymerase containing the amino acid sequence consisting of A1 to A12 by a conventional method, for example, by homology search using a computer.
- a known amino acid sequence database can be used for the search.
- a nucleic acid encoding the DNA polymerase selected in the step (1) is prepared, and a codon corresponding to A3 and / or A10 of the nucleic acid is converted into a codon of a basic amino acid residue. Is done.
- Such base substitution can be performed by a known method, and for example, a commercially available mutagenesis kit may be used.
- the full length of the nucleic acid encoding the mutant after mutagenesis may be chemically synthesized.
- mutations may be introduced into sites other than the 12 amino acid sequences shown in A1 to A12.
- a nucleic acid encoding the mutant can be prepared and introduced into an appropriate host to express the mutant. Codon optimization may be performed to enable expression of the mutant of interest in the host used or to increase the expression level. The codon optimization is preferably performed by a method commonly used in this field.
- the mutant can be produced by incorporating a nucleic acid encoding the amino acid sequence of the mutant into an appropriate expression vector.
- the expression vector preferably contains a nucleic acid encoding the mutant reverse transcriptase mutant of the present invention, and an expression control sequence operably linked to the nucleic acid.
- the expression control sequence is not particularly limited, and examples thereof include a promoter and a gene involved in the control of the promoter, a ribosome binding sequence, a polyadenylation signal, a transcription termination sequence (transcription terminator), an enhancer, and the like. Further, it may contain a gene encoding a marker (drug resistance gene, fluorescent marker, luminescent marker, etc.) used for selecting transformants.
- ⁇ ⁇ There is no particular limitation on the expression vector into which the nucleic acid encoding the DNA polymerase mutant having the reverse transcriptase activity of the present invention is inserted, as long as it is an expression vector commonly used in this field.
- a vector capable of autonomous replication in a host cell and a vector which can be integrated into a host chromosome can be used.
- a vector compatible with the host may be used.
- plasmid vector for example, a plasmid vector, a phage vector, a virus vector and the like can be used.
- plasmid vector plasmids suitable for the host to be used, for example, a plasmid derived from Escherichia coli, a plasmid derived from a bacterium belonging to the genus Bacillus, and a plasmid derived from yeast are well known to those skilled in the art, and many are commercially available. In the present invention, these known plasmids and variants thereof can be used.
- ⁇ phage for example, Charon4A, Charon21A, EMBL3, EMBL4, ⁇ gt10, ⁇ gt11, ⁇ ZAP
- virus vector for example, animal viruses such as retrovirus and vaccinia virus Insect viruses such as baculovirus can be used.
- many heterologous protein expression systems using yeast, insect cells, and mammalian cells as hosts have been constructed, and are already commercially available. These expression systems may be used for the production of the mutant DNA polymerase having reverse transcriptase activity of the present invention.
- the promoter mounted on the expression vector used in the production method of the present invention can be selected according to the host.
- promoters derived from Escherichia coli, phage, etc. such as trp promoter, lac promoter, PL promoter, PR promoter, etc.
- trp promoter trp promoter
- lac promoter lac promoter
- PL promoter PL promoter
- PR promoter PR promoter
- an expression system in which a phage-derived promoter and an RNA polymerase gene are combined for example, a pET expression system
- the expression vector of the present invention may further include a nucleic acid encoding an affinity tag.
- the nucleic acid encoding the affinity tag is inserted into a vector so that the fusion protein of the reverse transcriptase mutant of the present invention and the affinity tag is expressed.
- the affinity tag include a histidine (His) tag, a glutathione S-transferase (GST) tag, a maltose binding protein (maltose binding protein) (MBP) tag, and an 8-residue amino acid.
- a nucleic acid encoding a Strep (II) tag consisting of (Trp-Ser-His-Pro-Gln-Phe-Glu-Lys) and the like is exemplified.
- the tag may be added at any position on the 5 ′ end and / or 3 ′ end of the nucleic acid encoding the DNA polymerase mutant having a reverse transcriptase activity of the present invention, so that the expression and the tag function are not hindered. May be added as appropriate.
- the tag is preferably a tag that can be cleaved at the stage of purification of the expressed polypeptide.
- cleavable tags include fusion polypeptides such as Factor Xa, PreScission Protease, thrombin (Thrombin), enterokinase (enterokinase), and TEV protease (Tobacco Etch Virus Protease).
- fusion polypeptides such as Factor Xa, PreScission Protease, thrombin (Thrombin), enterokinase (enterokinase), and TEV protease (Tobacco Etch Virus Protease).
- a tag including a nucleic acid encoding a recognition sequence of a cleavage protease is exemplified.
- Method for improving DNA polymerase having reverse transcriptase activity of the present invention can be carried out as follows. That is, in a DNA polymerase having a reverse transcriptase activity comprising a sequence consisting of 12 amino acids represented by A1 to A12, the amino acids A3 and / or A10 are substituted with another basic amino acid residue.
- a DNA polymerase having a reverse transcriptase activity and having a sequence consisting of 12 amino acids represented by the following A1 to A12 can be selected as a candidate before mutagenesis.
- A1 is a branched amino acid residue
- A2 is a hydrophilic neutral amino acid residue or a hydrophobic aliphatic amino acid residue
- A3 is a hydrophilic neutral amino acid residue
- A4 is an acidic amino acid residue or a hydrophilic neutral amino acid residue
- A5 is a branched amino acid residue
- A6 is a hydrophobic aliphatic amino acid residue or a hydrophilic neutral amino acid residue
- A7 is a branched-chain amino acid residue
- A8 is a proline residue or a hydrophilic neutral amino acid residue
- A9 is a hydrophobic aromatic amino acid residue, a basic amino acid residue or a hydrophilic neutral amino acid residue
- A10 is an acidic amino acid residue or a basic amino acid residue
- A11 is an acidic amino acid residue
- A12 is a hydrophobic aliphatic amino acid residue.
- Examples of a method for selecting the candidate DNA polymerase having reverse transcriptase activity include a method of extracting a DNA polymerase containing the amino acid sequence consisting of A1 to A12 by a conventional method, for example, by homology search using a computer. .
- the search can be performed using a known amino acid sequence database.
- the sequence consisting of 12 amino acids is obtained by mutating a DNA polymerase having an amino acid sequence in which A1 is leucine, A3 is glutamine, A5 is leucine, A7 is isoleucine, A11 is glutamic acid, and A12 is alanine.
- Material can be used suitably.
- improvement of the DNA polymerase is achieved by substituting A3 and / or A10 amino acids with another basic amino acid residue. Specifically, the reverse transcription activity of DNA polymerase is improved, and the amount of reverse transcript (cDNA) produced per reaction time is increased.
- A3 and / or A10 with an amino acid selected from the group consisting of lysine, arginine and histidine. Particularly preferred is substitution with an arginine residue.
- a mutation may be further introduced at a site other than the 12 amino acid sequence represented by A1 to A12 as long as the reverse transcriptase activity and the nucleic acid amplification activity are not impaired.
- the DNA polymerase having the reverse transcriptase activity to be improved is not particularly limited, and examples thereof include Thermos thermophilus, Thermos aquaticus, Bacillus cardotenax, Bacillus stearothermophilus, and Alicyclo.
- thermostable polymerases derived from thermophilic bacteria, mesophilic DNA polymerases suitable for isothermal nucleic acid amplification, and amino acid substitutions, insertions or deletions thereof, or other variants thereof Both are included.
- it may be a Pol I type or a family A type DNA polymerase having low intrinsic reverse transcriptase activity.
- Tth DNA Polymerase Mutant The nucleotide sequence of a gene encoding a wild-type DNA polymerase derived from Thermus thermophilus (Tth) HB8 strain was determined by NCBI Reference Sequence No. WP_11222845.1. The amino acid sequence of the DNA polymerase is shown in SEQ ID NO: 1 in the sequence listing. Artificial genes having sequences in which mutations were introduced at specific sites in the amino acid sequence (sequences consisting of 12 amino acids represented by A1 to A12 of the present invention) were chemically synthesized.
- the resulting artificial gene was introduced into a plasmid pET6xHN-N (Takara Bio USA) using In-Fusion (registered trademark) HD Cloning Kit (Takara Bio USA).
- the resulting plasmid has a nucleotide sequence encoding a Tth DNA polymerase mutant with a histidine tag added to the N-terminal.
- Escherichia coli BL21 DE3 (manufactured by Takara Bio Inc.) was transformed with the plasmid, and cultured overnight at 37 ° C. on a 1.5% agarose LB plate containing 100 ⁇ g / mL ampicillin. Three single colonies were selected from this plate, inoculated on an LB medium containing 100 ⁇ g / mL of ampicillin (hereinafter referred to as LB-AP medium), and cultured at 37 ° C. overnight with shaking. Further, 300 ⁇ L of the above culture solution was inoculated into 25 mL of LB-AP medium, and cultured with shaking at 37 ° C. overnight. When the OD600 reached 0.6, IPTG having a final concentration of 1 mM was added to the culture solution, induction culture was further performed at 37 ° C. for 21 hours, and the cells were collected.
- LB-AP medium containing 100 ⁇ g / mL of ampicillin
- the cells obtained above were suspended in 2 mL of a solution containing 50 mM Tris-HCl pH 8.0 (4 ° C.), 100 mM NaCl, 1 mM EDTA (pH 8.0), and 5% glycerol (hereinafter referred to as Buffer S). Then, lysozyme (Sinopharm Chemical Reagent Co., Ltd.) was added to a final concentration of 0.1 mg / mL, and the mixture was shaken at 4 ° C. for 1 hour. After shaking, the mixture was centrifuged at 15,000 xg for 30 minutes at 4 ° C, and the supernatant was recovered. The collected supernatant was kept at 85 ° C. for 15 minutes and then centrifuged at 4 ° C. @ 15,000 ⁇ g for 30 minutes. The supernatant after heating was concentrated about 20 times by centrifugation using an Amicon@Ultra-0.5 mL column.
- the obtained concentrate was used in the following tests as a roughly purified solution of Tth ⁇ DNA polymerase mutant.
- the number of units of the enzyme used was as follows. Regarding DNA polymerase activity, activated salmon sperm DNA was used as a template / primer, and 10 nmol of all nucleotides was acid-insoluble in a reaction solution at pH 9.3 at 74 ° C. for 30 minutes. The activity taken into the product was calculated as 1 U.
- Tth DNA polymerase mutants 5U and 2.5U of Taq prepared in experimental methods (1) Body The reaction mixture in a final volume of 50 ⁇ L containing (Takara Bio Inc.) was prepared. As a control, a reaction solution containing wild-type Tth DNA polymerase was also prepared.
- RT-PCR conditions were set as a 45-cycle reaction in which treatment was performed at 90 ° C. for 30 seconds, 60 ° C. for 1 minute, and 95 ° C. for 1 minute, followed by 95 ° C. for 15 seconds and 56 ° C. for 45 seconds.
- the thermal cycler performed real-time PCR using TP-990 ⁇ ThermalCycler ⁇ Dice (registered trademark) Real ⁇ Time ⁇ SystemIII (manufactured by Takara Bio Inc.) to measure the Ct value.
- Example 1 Preparation of Tth DNA Polymerase Mutant
- an artificial gene encoding a mutant protein in which glutamine at position 682 in the wild-type amino acid sequence of Tth DNA polymerase was replaced with arginine was prepared.
- a recombinant plasmid having the obtained artificial gene was prepared, and the protein was expressed and the expressed protein was purified according to Experimental method 1 (1).
- the thus obtained Tth DNA polymerase mutant having a substitution mutation from glutamine at position 682 to arginine (Q682R) was designated as b13.
- glutamic acid at position 689 of the wild-type amino acid sequence of Tth DNA polymerase was replaced with arginine (E689R) Tth DNA polymerase mutant (designated b46), glutamine at position 682 was replaced with arginine, and glutamic acid at position 689 was replaced with glutamic acid.
- the amino acid sequence and the nucleic acid sequence of the mutant protein are shown in SEQ ID NOs: 5 to 10.
- Example 2 Evaluation Test 1 for Reverse Transcription Activity of Tth DNA Polymerase Mutant For the mutant Tth DNA polymerase and the wild-type Tth DNA polymerase prepared in Example 1, a reverse transcription activity evaluation test was performed in accordance with the experimental method (2). Normally, when a wild-type Tth DNA polymerase is used, the reverse transcription reaction is usually performed at 60 ° C. for 30 minutes, but in this example, the performance was compared with a short reverse transcription reaction time of 60 ° C. for 1 minute. Table 1 shows the results. Since the Ct value is inversely proportional to the initial amount of the target, it can be used to calculate the initial copy number of DNA. For example, when the Ct value is smaller by one (minus), the amount of DNA serving as a template for PCR is twice as large.
- Example 3 Fusion protein of PIP box and Tth mutant The fusion protein of the Tth DNA polymerase mutant and the PCNA binding domain described in Example 1 was examined. First, according to the method described in Example 4 of International Publication WO2017 / 090685, 3 PIPs having three PIP boxes having the amino acid sequence of SEQ ID NO: 11 in the sequence listing are tandemly arranged on the N-terminal side of each Tth DNA polymerase mutant, and wild-type. A fusion protein of Tth DNA polymerase (PIP-L14-PIP-L14-PIP-L15-Tth DNA polymerase) was prepared. The fusion protein was named 3PIP-wild type.
- fusion proteins of 3PIP and the b13, b46 and b13b46 mutants described in Example 1 were also prepared, and these were named 3PIP-b13, 3PIP-b46 and 3PIP-b13b46.
- a Puf PCNA D143R mutant (PCNA13), which is a polymerase-related factor that recognizes the PIP box, was prepared by the method described in Examples in International Publication WO2007 / 004654.
- RNA used as a template for the reverse transcription reaction was prepared as follows.
- the Ministry of Health, Labor and Welfare, Pharmaceutical and Food Bureau, Food Safety Department, Surveillance and Safety Division notified “Norovirus Detection Methods” (Attachment No. 1105001 issued by the Food Safety Inspection on November 5, 2003; Last revision: October 22, 2013)
- RNA of nucleotide sequence including a region to be PCR-amplified with primers for GI detection and GII detection having the same nucleotide sequence as described in JASJ 1022 No. 1 (hereinafter referred to as “official method”) was prepared by a conventional method.
- reaction solution having a final volume of 25 ⁇ L containing 5 U of the above-mentioned 3PIP-Tth ⁇ DNA polymerase mutant was prepared.
- reaction solutions containing wild-type and wild-type Tth ⁇ DNA polymerase with 3PIP added to the N-terminal were also prepared.
- RT-PCR conditions were as follows: treatment at 58 ° C. for 5 minutes and 95 ° C. for 30 seconds, followed by 5 cycles of reaction at 95 ° C. for 5 seconds and 56 ° C. for 1 minute.
- a 40-cycle reaction was set as one cycle.
- the thermal cycler is the same as in the second embodiment.
- Table 2 shows the results of the GI detection. Similarly, the results of GII detection are shown in Table 3.
- any of b13, b46 and b13b46 of the present invention in which the PIP box was added to the N-terminal compared to the wild type and the wild-type in which the PIP box was added to the N-terminal was confirmed.
- Example 4 Reverse transcription activity evaluation test 2 of Tth DNA polymerase mutant
- the b13 and b13b46 mutants in which the ability of the reverse transcription reaction was improved in Example 2 were evaluated by detecting norovirus in actual samples. That is, a norovirus-positive stool sample collected from a subject with informed consent was suspended in PBS to about 10% (w / v), and then centrifuged at 15,000 rpm for 5 minutes. . 1 ⁇ L of the supernatant thus obtained was used for the following reaction.
- a reaction solution containing wild-type Tth DNA polymerase was also prepared.
- the RT-PCR conditions were Tth D In the case of A polymerase, after treating at 90 ° C. for 3 minutes, 58 ° C. for 5 minutes or 30 minutes, and at 95 ° C. for 30 seconds, a 5-cycle reaction with 95 ° C. for 5 seconds and 56 ° C.
- the reaction was set to 40 cycles in which 5 seconds and 30 seconds at 56 ° C.
- One cycle of the Tth DNA polymerase mutant was treated at 90 ° C. for 3 minutes, 58 ° C. for 5 minutes and 95 ° C. for 30 seconds, and then 95 ° C. for 5 seconds.
- the reaction was set to 5 cycles with 30 seconds at 56 ° C. and 40 cycles with 5 seconds at 90 ° C. and 30 seconds at 56 ° C.
- the thermal cycler was the same as in Example 2.
- Tth ⁇ DNA polymerase was able to be detected only when the reverse transcription reaction was performed at 58 ° C. for 30 minutes for the detection of norovirus GI in feces.
- the b13 and b13b46 mutants of the present invention could be detected even when the reverse transcription reaction was performed at a short time of 58 ° C. for 5 minutes. From this, it was confirmed that the mutant of the present invention maintained the improvement of the reverse transcriptase reaction even in the detection using the actual sample.
- Example 5 Reverse Transcription Activity Evaluation Test 3 of Tth DNA Polymerase Mutant A comparison was made between the Tth DNA polymerase mutant of the present invention and a Tth DNA polymerase mutant that was previously reported to be capable of performing a reverse transcription reaction efficiently at high temperature. According to the description in Japanese Patent No. 3844975, a crude enzyme solution of a Tth DNA polymerase mutant was prepared by the method of Experimental Method (1). That is, at position 681 in the amino acid sequence described in Taq DNA polymerase (Genbank Acc. No. BAA067755.1), NCBI Reference Sequence No.
- Tth DNA polymerase Since the amino acid sequence of Tth DNA polymerase based on the amino acid sequence described in WP_01128284 corresponds to position 683, a Tth DNA polymerase mutant in which glutamic acid at position 683 of the amino acid sequence is substituted with phenylalanine, lysine, leucine, arginine, or tyrosine was used. Prepared. These amino acid variants were named E683F, E683K, E683L, E683R, and E683Y variants, respectively.
- the Tth ⁇ DNA polymerase mutant in which the glutamic acid at position 683 was substituted failed to produce an amplification product derived from the template, or had a higher Ct value than the Tth ⁇ DNA polymerase mutant of the present invention.
- it means that the amount of the initial template DNA at the start of the PCR is reduced, that is, the amount of the cDNA by the reverse transcription reaction before the PCR is about ⁇ or less, and As a result, it was confirmed that the reverse transcription reaction activity was superior to that prepared by the conventional technique.
- Escherichia coli BL21 DE3 (manufactured by Takara Bio Inc.) was transformed with the plasmid, and cultured overnight at 37 ° C. on a 1.5% agarose LB plate containing 100 ⁇ g / mL ampicillin. Three single colonies were selected from this plate, inoculated on an LB medium containing 100 ⁇ g / mL of ampicillin (hereinafter referred to as LB-AP medium), and cultured at 37 ° C. overnight with shaking. Further, 30 ml of the above culture solution was inoculated into 3 L of LB-AP medium, and cultured at 37 ° C. overnight with shaking. When the OD600 reached 0.6, IPTG having a final concentration of 1 mM was added to the culture solution, induction culture was further performed at 37 ° C. for 4 hours, and the cells were collected.
- LB-AP medium containing 100 ⁇ g / mL of ampicillin
- 3 g of the cells obtained above were suspended in 12 ml of a buffer (50 mM Tris ⁇ HCl pH 7.0 (4 ° C.), 4 ⁇ M PMSF, 1 mM DTT, 10% glycerol), and the mixture was stirred with Sonic 180 W for 10 minutes. Thereafter, the mixture was centrifuged at 10,000 rpm for 30 minutes at 4 ° C. The supernatant was recovered and heat-treated at 60 ° C. for 30 minutes. After the heat-treated supernatant was cooled on ice for 30 minutes, it was centrifuged at 11,000 rpm for 30 minutes (4 ° C.) to recover the supernatant.
- a buffer 50 mM Tris ⁇ HCl pH 7.0 (4 ° C.), 4 ⁇ M PMSF, 1 mM DTT, 10% glycerol
- the obtained supernatant was subjected to DEAE Sepharose Fast Flow (manufactured by GE Healthcare), CM Sepharose Fast Flow (manufactured by GE Healthcare), Sephadex-G100, Heparin Sepharose (manufactured by GE Healthcare, Inc.)
- a purified solution of the Bca DNA polymerase mutant protein was prepared in the following order, and used in the following tests.
- the number of units of the enzyme used was as follows.
- DNA polymerase activity activated salmon sperm DNA was used as a template / primer, and 10 nmol of all nucleotides was acid-insoluble in a reaction solution at pH 9.3 at 74 ° C. for 30 minutes. The activity taken into the product was calculated as 1 U.
- the Escherichia coli BL21 DE3 strain transformed with the plasmid was cultured in the same manner as described in Experimental method (3) to collect the cells.
- a purified solution of Aac DNA polymerase mutant was prepared from 3 g of the bacterial cells obtained above by the same purification method described in Experimental method (3), and used in the following tests.
- the number of units of the enzyme used is the same as in the case of Bca @ DNA polymerase.
- Escherichia coli BL21 DE3 strain transformed with the plasmid was cultured in the same manner as described in Experimental method (3), and cells were collected.
- Activated salmon sperm DNA was prepared at a final concentration of 100 ⁇ M [3H] -dTTP and a final concentration of 0.25 mg / ml. That is, using activated salmon sperm DNA as a template / primer, the activity of incorporating 10 nmol of all nucleotides into the acid-insoluble precipitate in 30 minutes at 74 ° C. in the above-mentioned reaction solution for activity measurement was measured as 1 U.
- the reverse transcription activity was measured for the Bca, Aac, and Taq DNA polymerase mutants obtained in (3), (4), and (5) above.
- the reverse transcription activity was measured using a reaction solution of 50 mM Tris-HCl, pH 8.3 (37 ° C.), 5 mM Tris-HCl pH 7.5 (37 ° C.), 85 mM KCl, 8 mM MgCl 2 , 10 mM DTT, 0.1% NP-40. , 0.02 mg / ml Poly (A), 2.5 mM dTTP, and 100 ⁇ Ci / ml [3H] -dTTP.
- Experimental method (7) Method for evaluating reverse transcription activity of Bca, Aac, and Taq DNA polymerase mutant The following method was used for the Bca, Aac, and Taq DNA polymerase mutants obtained in (3), (4), and (5) above. Tested the reverse transcription reaction. In the test, a part of the components of the BcaBEST (trademark) RNA PCR Kit (manufactured by Takara Bio Inc.) was used.
- 2 ⁇ Bca 1st Buffer included in the kit 25 mM MgSO 4, RNase Inhibitor (40 U / ul), 10 mM dNTP, and a final concentration of 0 having the base sequence of SEQ ID NO: 26 in the Sequence Listing are 0. 0.5 ⁇ M of reverse transcription primer, 500 ⁇ M of final concentration of dNTP, and 10 ng / ⁇ L of final concentration of HL60 total RNA (manufactured by Takara Bio Inc.) as a template were added to Bca prepared by Experimental Methods (3), (4) and (5).
- Aac and 0.5 ⁇ l of a Taq DNA polymerase mutant purified solution were added to prepare 10 ⁇ L of a reverse transcription reaction solution.
- reaction solutions containing wild-type Bca, Aac, and Taq DNA polymerase were also prepared.
- ⁇ PCR conditions were set to a 40-cycle reaction in which the initial denaturation was performed at 90 ° C for 30 seconds, followed by one cycle of 95 ° C for 5 seconds and 60 ° C for 30 seconds.
- the thermal cycler performed real-time PCR using TP-990 ⁇ ThermalCycler ⁇ Dice (registered trademark) Real ⁇ Time ⁇ SystemIII (manufactured by Takara Bio Inc.) to measure the Ct value.
- Example 6 Evaluation test 1 for reverse transcription activity of Bca, Aac and Taq mutant Evaluation test 1 was performed on the Bca, Aac and Taq DNA polymerase mutants obtained in the above (3), (4) and (5) by the method described in the above experimental method (6). Table 5 shows the results.
- each DNA polymerase mutant b13b46 has a mutation corresponding to the “Q682R + E689R” mutation in the Tth DNA polymerase mutant b13b46 (that is, the amino acids at positions corresponding to positions 682 and 689 in the amino acid sequence of Tth DNA polymerase are different from each other). Arginine).
- the Bca (b13b46) mutant prepared as compared to the Bca native form has increased reverse transcription activity while maintaining the polymerase activity, and has about twice the reverse transcription activity as compared to the native form. Has improved.
- the reverse transcription activity of the Aac (b13b46) mutant was improved about 4 times as compared with the native form while maintaining the polymerase activity.
- the Taq (b13b46) mutant improved the reverse transcription activity by about 9-fold compared to the native form while maintaining the polymerase activity.
- Example 7 Evaluation test 2 for reverse transcription activity of Bca, Aac and Taq mutant For the Bca, Aac and Taq DNA polymerase mutants obtained in (3), (4) and (5) above, the amount of cDNA synthesized was confirmed and the reverse transcription activity was evaluated.
- Evaluation test 2 was performed by the method described in the above-mentioned experimental method (7).
- Table 6 shows the results.
- the initial template DNA amount at the time of PCR was 510- to 1000-fold or more as compared with the wild-type enzyme in each mutant.
- An increase in the amount of template DNA means that there was an increase in the amount of cDNA due to the reverse transcription reaction before PCR, and the mutant had a 510 to 1000-fold or more improvement in the ability of the wild-type in the reverse transcription reaction.
- the present invention can improve the reverse transcriptase activity of DNA polymerases classified into Pol I type or Family A type.
- the DNA polymerase having a reverse transcriptase activity suitable for performing a reverse transcription reaction and a nucleic acid amplification reaction in the same container.
- a reaction with high reverse transcription efficiency can be performed even when an RNA having a strong secondary structure, which has been difficult to perform a reverse transcription reaction, is used as a template.
- detection at the same level or higher can be performed in a shorter time than in the conventional enzyme.
- the DNA polymerase having reverse transcriptase activity of the present invention is useful in a wide range of fields such as genetic engineering, biology, medicine, and agriculture.
- SEQ ID NO: 1 DNA polymerase I Thermus thermophilus
- SEQ ID NO: 2 PCR forward Primer lambda RNA
- SEQ ID NO: 3 PCR Reverse Primer lambda RNA
- SEQ ID NO: 4 Probe lambda RNA.
- DNA polymerase variant Tth b13 SEQ ID NO: 6 DNA polymerase variant Tth b13 SEQ ID NO: 7: DNA polymerase variant Tth b46 SEQ ID NO: 8: DNA polymerase variant Tth b46 SEQ ID NO: 9: DNA polymerase variant Tth b13 b46 SEQ ID NO: 10: DNA polymerase variant Tth b13 b46 SEQ ID NO: 11: PIP-L14-PIP-L14-PIP-L15 Tth SEQ ID NO: 12: PCR forward Primer COG1F SEQ ID NO: 13: PCR Reverse Primer COG1R SEQ ID NO: 14: PCR forward Primer COG2F SEQ ID NO: 15: PCR Reverse Primer COG2R SEQ ID NO: 16: Probe RING1-TP (a).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
A1は、分枝鎖アミノ酸残基であり;
A2は、親水性の中性アミノ酸残基あるいは疎水性の脂肪族アミノ酸残基であり;
A3は、親水性の中性アミノ酸残基であり;
A4は、酸性アミノ酸残基あるいは親水性の中性アミノ酸残基であり;
A5は、分枝鎖アミノ酸残基であり;
A6は、疎水性の脂肪族アミノ酸残基あるいは親水性の中性アミノ酸残基であり、
A7は、分枝鎖アミノ酸残基であり;
A8は、プロリン残基あるいは親水性の中性アミノ酸残基であり;
A9は、疎水性の芳香族アミノ酸残基、塩基性アミノ酸残基あるいは親水性の中性アミノ酸残基であり;
A10は、酸性アミノ酸残基あるいは塩基性アミノ酸残基であり;
A11は、酸性アミノ酸残基であり;
A12は、疎水性の脂肪族アミノ酸残基であり;及び
前記のA3及び/又はA10のアミノ酸が変異導入前のものとは別の塩基性アミノ酸残基に置換されていることを特徴とする、逆転写酵素活性を有するDNAポリメラーゼ変異体、に関する。
(1)以下のA1~A12の12アミノ酸からなる配列を含む、DNAポリメラーゼを選択する工程;
A1は、分枝鎖アミノ酸残基であり;
A2は、親水性の中性アミノ酸残基あるいは疎水性の脂肪族アミノ酸残基であり;
A3は、親水性の中性アミノ酸残基であり;
A4は、酸性アミノ酸残基あるいは親水性の中性アミノ酸残基であり;
A5は、分枝鎖アミノ酸残基であり;
A6は、疎水性の脂肪族アミノ酸残基あるいは親水性の中性アミノ酸残基であり、
A7は、分枝鎖アミノ酸残基であり;
A8は、プロリン残基あるいは親水性の中性アミノ酸残基であり;
A9は、疎水性の芳香族アミノ酸残基、塩基性アミノ酸残基あるいは親水性の中性アミノ酸残基であり;
A10は、酸性アミノ酸残基あるいは塩基性アミノ酸残基であり;
A11は、酸性アミノ酸残基であり;
A12は、疎水性の脂肪族アミノ酸残基であり;及び
(2)工程(1)で選択されたDNAポリメラーゼの、上記12アミノ酸からなる配列におけるA3及び/又はA10のアミノ酸が変異導入前のものとは別の塩基性アミノ酸残基に置換する工程、を含む方法に関する。
A1は、分枝鎖アミノ酸残基であり;
A2は、親水性の中性アミノ酸残基あるいは疎水性の脂肪族アミノ酸残基であり;
A3は、親水性の中性アミノ酸残基であり;
A4は、酸性アミノ酸残基あるいは親水性の中性アミノ酸残基であり;
A5は、分枝鎖アミノ酸残基であり;
A6は、疎水性の脂肪族アミノ酸残基あるいは親水性の中性アミノ酸残基であり、
A7は、分枝鎖アミノ酸残基であり;
A8は、プロリン残基あるいは親水性の中性アミノ酸残基であり;
A9は、疎水性の芳香族アミノ酸残基、塩基性アミノ酸残基あるいは親水性の中性アミノ酸残基であり;
A10は、酸性アミノ酸残基あるいは塩基性アミノ酸残基であり;
A11は、酸性アミノ酸残基であり;及び
A12は、疎水性の脂肪族アミノ酸残基である、に関する。
A1は、ロイシン;
A2は、セリンあるいはアラニン;
A3は、グルタミン;
A4は、グルタミン酸あるいはアスパラギン;
A5は、ロイシン;
A6は、アラニンあるいはアスパラギン;
A7は、イソロイシン;
A8は、プロリン、セリンあるいはスレオニン;
A9は、チロシン、アルギニンあるいはグルタミン;
A10は、グルタミン酸あるいはリシン;
A11は、グルタミン酸;
A12は、アラニン;及び
前記のA3及び/又はA10のアミノ酸が変異導入前のものとは別の塩基性アミノ酸残基に置換された変異体が好ましく、例えば、A3及び/又はA10のアミノ酸がリシン、アルギニン及びヒスチジンからなる群より選択されたアミノ酸に置換されたDNAポリメラーゼの変異体であってもよい。
本発明の第一の態様は、逆転写酵素反応と核酸増幅反応に適したDNAポリメラーゼ変異体に関するものである。本発明の変異体は、A1~A12の12アミノ酸からなる配列を含む、逆転写酵素活性を有するDNAポリメラーゼの変異体であって、ここで
A1は、分枝鎖アミノ酸残基であり;
A2は、親水性の中性アミノ酸残基あるいは疎水性の脂肪族アミノ酸残基であり;
A3は、親水性の中性アミノ酸残基であり;
A4は、酸性アミノ酸残基あるいは親水性の中性アミノ酸残基であり;
A5は、分枝鎖アミノ酸残基であり;
A6は、疎水性の脂肪族アミノ酸残基あるいは親水性の中性アミノ酸残基であり、
A7は、分枝鎖アミノ酸残基であり;
A8は、プロリン残基あるいは親水性の中性アミノ酸残基であり;
A9は、疎水性の芳香族アミノ酸残基、塩基性アミノ酸残基あるいは親水性の中性アミノ酸残基であり;
A10は、酸性アミノ酸残基あるいは塩基性アミノ酸残基であり;
A11は、酸性アミノ酸残基であり;
A12は、疎水性の脂肪族アミノ酸残基であり、そして前述のA3及び/又はA10のアミノ酸が別の塩基性アミノ酸残基に置換された変異体である。
A1は、ロイシン;
A2は、セリンあるいはアラニン;
A3は、グルタミン;
A4は、グルタミン酸あるいはアスパラギン;
A5は、ロイシン;
A6は、アラニンあるいはアスパラギン;
A7は、イソロイシン;
A8は、プロリン、セリンあるいはスレオニン;
A9は、チロシン、アルギニンあるいはグルタミン;
A10は、グルタミン酸あるいはリシン;
A11は、グルタミン酸;
A12は、アラニン;及び
前記のA3及び/又はA10のアミノ酸が変異導入前のものとは別の塩基性アミノ酸残基に置換された変異体が例示され、例えば、A3及び/又はA10のアミノ酸がリシン、アルギニン及びヒスチジンからなる群より選択されたアミノ酸に置換されたDNAポリメラーゼの変異体であってもよい。
本発明の組成物は、前記の本発明の逆転写酵素活性を有するDNAポリメラーゼ変異体を含む組成物を意味する。本発明の組成物の一態様としては、逆転写反応と核酸増幅反応に適した組成物であり、上記1.で述べた本発明の逆転写酵素反応と核酸増幅反応に適したDNAポリメラーゼ変異体に加え、例えば逆転写反応とポリメラーゼ連鎖反応(RT-PCR)に必要な成分、例えば、二価金属塩、dNTPs、緩衝成分、還元剤、滅菌水等を含有する。また本発明の組成物は、増幅/検出すべきRNAが明らかな場合には適切なプライマーを含んでいてもよい。一方、逆転写反応と等温核酸増幅反応に適した組成物の場合も逆転写反応と等温核酸増幅反応に必要な成分を含む限りは、上記と同様の成分を含む組成物が好適である。
本発明の逆転写酵素反応と核酸増幅反応に適したDNAポリメラーゼ変異体の製造方法は、上記1.に記載のDNAポリメラーゼ変異体の製造方法に関するものである。
(1)以下のA1~A12の12アミノ酸からなる配列を含む、DNAポリメラーゼを選択する工程;
A1は、分枝鎖アミノ酸残基であり;
A2は、親水性の中性アミノ酸残基あるいは疎水性の脂肪族アミノ酸残基であり;
A3は、親水性の中性アミノ酸残基であり;
A4は、酸性アミノ酸残基あるいは親水性の中性アミノ酸残基であり;
A5は、分枝鎖アミノ酸残基であり;
A6は、疎水性の脂肪族アミノ酸残基あるいは親水性の中性アミノ酸残基であり、
A7は、分枝鎖アミノ酸残基であり;
A8は、プロリン残基あるいは親水性の中性アミノ酸残基であり;
A9は、疎水性の芳香族アミノ酸残基、塩基性アミノ酸残基あるいは親水性の中性アミノ酸残基であり;
A10は、酸性アミノ酸残基あるいは塩基性アミノ酸残基であり;
A11は、酸性アミノ酸残基であり;
A12は、疎水性の脂肪族アミノ酸残基であり;及び
(2)工程(1)で選択されたDNAポリメラーゼの、上記12アミノ酸からなる配列におけるA3及び/又はA10のアミノ酸が変異導入前のものとは別の塩基性アミノ酸残基に置換する工程、を含む方法が例示される。
本発明の逆転写酵素活性を有するDNAポリメラーゼの改良方法は、以下のようにして実施することができる。即ち、A1~A12に示す12アミノ酸からなる配列を含む、逆転写酵素活性を有するDNAポリメラーゼにおいて、A3及び/又はA10のアミノ酸を別の塩基性アミノ酸残基に置換することを特徴とする。
A2は、親水性の中性アミノ酸残基あるいは疎水性の脂肪族アミノ酸残基であり;
A3は、親水性の中性アミノ酸残基であり;
A4は、酸性アミノ酸残基あるいは親水性の中性アミノ酸残基であり;
A5は、分枝鎖アミノ酸残基であり;
A6は、疎水性の脂肪族アミノ酸残基あるいは親水性の中性アミノ酸残基であり、
A7は、分枝鎖アミノ酸残基であり;
A8は、プロリン残基あるいは親水性の中性アミノ酸残基であり;
A9は、疎水性の芳香族アミノ酸残基、塩基性アミノ酸残基あるいは親水性の中性アミノ酸残基であり;
A10は、酸性アミノ酸残基あるいは塩基性アミノ酸残基であり;
A11は、酸性アミノ酸残基であり;及び
A12は、疎水性の脂肪族アミノ酸残基である。
(1)Tth DNAポリメラーゼ変異体の調製方法
Thermus thermophilus(Tth) HB8株由来の野生型DNAポリメラーゼをコードする遺伝子の塩基配列は、NCBI Reference Sequence No.WP_011228405.1に開示されている。当該DNAポリメラーゼのアミノ酸配列を配列表の配列番号1に示す。当該アミノ酸配列中の特定の部位(本発明のA1~A12に示す12アミノ酸からなる配列部分)に変異を導入した配列の人工遺伝子を、それぞれ化学的に合成した。得られた人工遺伝子は、In-Fusion(登録商標)HD Cloning Kit(タカラバイオUSA社製)を用いて、プラスミドpET6xHN-N(タカラバイオUSA社製)に導入した。得られたプラスミドは、N末端側にヒスチジンタグが付加されたTth DNAポリメラーゼ変異体をコードする塩基配列を有している。
上記(1)で得られたTth DNAポリメラーゼ変異体について、以下の方法で逆転写反応を試験した。即ち、当該Tth DNAポリメラーゼ変異体粗抽出溶液について、5×RT-PCR緩衝液(終濃度50mM バイシン緩衝液(pH8.2)、終濃度115mM 酢酸カリウム、終濃度8%グリセロール、)、終濃度2.5mM 酢酸マンガン、終濃度0.1% BSA、配列表の配列番号2及び3記載の塩基配列を有する終濃度0.2μMのプライマー対、配列表の配列番号4記載の塩基配列を有する終濃度0.2μMのプローブ、終濃度0.3mM dNTP、鋳型となる鎖長4.4kbのRNA(λDNA(GenBank ACC. No.J02459.1)の核酸番号12697から17090の領域に相当するRNA。1×107コピー相当)、実験方法(1)で調製したTth DNAポリメラーゼ変異体5U並びに2.5UのTaq抗体(タカラバイオ社製)を含む最終容量50μLの反応液を調製した。対照として、野生型Tth DNAポリメラーゼを含む反応液も調製した。
実験方法(1)に従って、Tth DNAポリメラーゼの野生型アミノ酸配列において、682位のグルタミンをアルギニンに置き換えた変異体タンパク質をコードする人工遺伝子を調製した。得られた人工遺伝子を保持する組換えプラスミドを作製し、実験方法1(1)にしたがってタンパク発現ならびに発現されたタンパク質の精製を行った。こうして得られた、682位のグルタミンからアルギニンへの置換変異(Q682R)を有するTth DNAポリメラーゼ変異体をb13と命名した。同様にして、Tth DNAポリメラーゼの野生型アミノ酸配列の689位のグルタミン酸をアルギニンに置き換えた(E689R)Tth DNAポリメラーゼ変異体(b46と命名した)、682位のグルタミンをアルギニンに、689位のグルタミン酸をアルギニンにそれぞれ置き換えた(Q682R+E689R)Tth DNAポリメラーゼ変異体(b13b46と命名した)を調製した。前記変異体タンパク質のアミノ酸配列及び核酸配列を配列番号5~10に示す。
実施例1で調製したTth DNAポリメラーゼ変異体及び野生型Tth DNAポリメラーゼについて、実験方法(2)にしたがって逆転写活性評価試験を行った。通常野生型Tth DNAポリメラーゼを使用する場合、逆転写反応は60℃ 30分間が標準であるが、本実施例では60℃ 1分間という短い逆転写反応時間でその性能を比較した。その結果を表1に示す。Ct値はターゲットの初期量に反比例するため、DNAの初期コピー数の算出に使用できる。例えば、Ct値が1小さい(マイナス)とPCRの鋳型となるDNA量が2倍多いことになる。
実施例1記載のTth DNAポリメラーゼ変異体とPCNA結合ドメインの融合タンパク質について検討した。まず国際公開WO2017/090685号パンフレット 実施例4記載の方法に従い、各Tth DNAポリメラーゼ変異体のN末端側に配列表の配列番号11記載のアミノ酸配列を有するPIPボックスが3つ縦列した3PIPと野生型Tth DNAポリメラーゼの融合タンパク質(PIP-L14-PIP-L14-PIP-L15-Tth DNAポリメラーゼ)を作製した。当該融合タンパク質は、3PIP-野生型と命名した。同様に3PIPと実施例1で説明したb13、b46ならびにb13b46変異体との融合タンパク質も作製したこれらは、3PIP-b13、3PIP-b46並びに3PIP-b13b46と命名した。また、PIPボックスを認識するポリメラーゼ関連因子であるPuf PCNA D143R変異体(PCNA13)は、国際公開WO2007/004654号パンフレット 実施例記載の方法で調製した。
上記実施例2で逆転写反応の能力向上が認められたb13並びにb13b46変異体について、実検体でのノロウイルス検出によって評価を行った。即ち、インフォームドコンセントの得られた被験者より採取されたノロウイルス陽性の糞便検体を約10%(w/v)となるようPBSに懸濁した後、15,000rpmにて5分間遠心処理を行った。こうして得られた上清1μLを以下の反応に使用した。即ち、前記糞便上清液1μL、5×RT-PCR緩衝液(終濃度50mM トリシン緩衝液(pH8.15)、終濃度50mM 酢酸カリウム、終濃度8%グリセロール、終濃度1%のDMSO、終濃度2.5mM 酢酸マンガン、終濃度0.1% BSA、公定法で定められた終濃度0.2μMのGIプライマー対、終濃度0.2μMのGI検出用プローブ、終濃度0.3mMのdNTP、前述の3PIP-Tth DNAポリメラーゼ変異体5U、終濃度4%のポリ(エチレングリコール)4-ノニルフェニル 3-スルホプロピルエーテル並びに2.5UのTaq抗体(タカラバイオ社製)を含む最終容量25μLの反応液を含む調製した。対照として、野生型Tth DNAポリメラーゼを含む反応液も調製した。RT-PCR条件は、Tth DNAポリメラーゼの場合は、90℃ 3分、58℃ 5分あるいは30分、95℃ 30秒間処理した後、95℃ 5秒、56℃ 30秒を1サイクルとする5サイクル反応、連続して90℃ 5秒、56℃ 30秒を1サイクルとする40サイクル反応に設定した。Tth DNAポリメラーゼ変異体の場合は、90℃ 3分、58℃ 5分、95℃ 30秒間処理した後、95℃ 5秒、56℃ 30秒を1サイクルとする5サイクル反応、連続して90℃ 5秒、56℃ 30秒を1サイクルとする40サイクル反応に設定した。サーマルサイクラーは、実施例2と同じである。
本発明のTth DNAポリメラーゼ変異体と、以前に高温かつ効率よく逆転写反応ができると報告されたTth DNAポリメラーゼ変異体との比較を行った。日本特許第3844975号公報の記載に従い、実験方法(1)の方法でTth DNAポリメラーゼ変異体の粗酵素液を調製した。即ち、Taq DNAポリメラーゼ(Genbank Acc.No.BAA06775.1)記載のアミノ酸配列の681位が、NCBI Reference Sequence No.WP_011228405記載のアミノ酸配列に基づくTth DNAポリメラーゼのアミノ酸配列では683位に相当することから、前記アミノ酸配列の683位のグルタミン酸をフェニルアラニン、リシン、ロイシン、アルギニンあるいはチロシンに置換変異したTth DNAポリメラーゼ変異体を調製した。これらのアミノ酸変異体をそれぞれE683F、E683K、E683L、E683R、E683Y変異体と命名した。
(3)Bca DNAポリメラーゼ変異体の調製方法
Bacillus caldotenax(Bca)由来の野生型DNAポリメラーゼをコードする遺伝子の塩基配列は、NCBI Reference Sequence No.NZ_CP025074.1に開示されている。当該DNAポリメラーゼのアミノ酸配列を配列表の配列番号23に示す。当該アミノ酸配列中の特定の部位(本発明のA1~A12に示す12アミノ酸からなる配列部分)に変異を導入した配列の人工遺伝子を、それぞれ化学的に合成し、実験方法(1)記載の方法でN末端側にヒスチジンタグが付加された Bca DNAポリメラーゼ変異体をコードする遺伝子を含むプラスミドを調製した。
得られた上清は、DEAE Sepharose Fast Flow(GE Healthcare社製)、CM Sepharose Fast Flow(GE Healthcare社製)、Sephadex-G100、Heparin Sepharose(GE Healthcare社製)、Q Sepharose(GE Healthcare社製)の順に用いてBca DNAポリメラーゼ変異体タンパクの精製液を調製し、以下の試験に使用した。なお使用酵素のユニット数は、DNAポリメラーゼ活性については、活性化サケ精子DNAを鋳型/プライマーとして用い、pH9.3の反応液中にて74℃において、30分間に10nmolの全ヌクレオチドを酸不溶性沈殿物に取り込む活性を1Uとして算出した。
(4)Aac DNAポリメラーゼ変異体の調製方法
Alicyclobacillus acidocaldarius(Aac)由来の野生型DNAポリメラーゼをコードする遺伝子の塩基配列は、NCBI Reference Sequence No.AB275481.1に開示されている。当該DNAポリメラーゼのアミノ酸配列を配列表の配列番号24に示す。当該アミノ酸配列中の特定の部位(本発明のA1~A12に示す12アミノ酸からなる配列部分)に変異を導入した配列の人工遺伝子を、それぞれ化学的に合成し、実験方法(1)記載の方法でN末端側にヒスチジンタグが付加された Aac DNAポリメラーゼ変異体をコードする遺伝子を含むプラスミドを調製した。
(5)Taq DNAポリメラーゼ変異体の調製方法
Thermus aquaticus(Taq)由来の野生型DNAポリメラーゼをコードする遺伝子の塩基配列は、NCBI Reference Sequence No.D32013.1に開示されている。当該DNAポリメラーゼのアミノ酸配列を配列表の配列番号25に示す。当該アミノ酸配列中の特定の部位(本発明のA1~A12に示す12アミノ酸からなる配列部分)に変異を導入した配列の人工遺伝子を、それぞれ化学的に合成し、実験方法(1)記載の方法でN末端側にヒスチジンタグが付加された Taq DNAポリメラーゼ変異体をコードする遺伝子を含むプラスミドを調製した。
なお使用酵素のユニット数は、Bca DNAポリメラーゼの場合と同じである。
(6)Bca、Aac、Taq DNAポリメラーゼ変異体の逆転写活性評価方法
上記(3)、(4)、(5)で得られたBca、Aac、Taq DNAポリメラーゼ変異体についてポリメラーゼ(Pol)活性を測定した。前記Pol活性は、反応液として終濃度25mM TAPS緩衝液(pH9.3、25℃)、終濃度50mM KCl、終濃度2mM MgCl2、終濃度0.1mM DTT、終濃度 各200μM dATP・dGTP・dCTP、終濃度100μM [3H]-dTTP、終濃度0.25mg/ml活性化サケ精子DNAを調製して行った。即ち、活性化サケ精子DNAを鋳型/プライマーとして用い、上記の活性測定用反応液中にて74℃において、30分間に10nmolの全ヌクレオチドを酸不溶性沈殿物に取り込む活性を1Uとして測定した。
(7)Bca、Aac並びにTaq DNAポリメラーゼ変異体の逆転写活性評価方法
上記(3)、(4)、(5)で得られたBca、Aac並びにTaq DNAポリメラーゼ変異体について、以下の方法で逆転写反応を試験した。
当該試験では、BcaBEST(商標) RNA PCR Kit(タカラバイオ社製)の構成品の一部を利用した。即ち、それぞれのDNAポリメラーゼ変異体精製溶液について、該キット付属の2×Bca 1st Buffer、25mM MgSO4、RNase Inhibitor (40U/ul)、10mM dNTP、配列表の配列番号26の塩基配列を有する終濃度0.5μMの逆転写プライマー、終濃度500μMのdNTP、鋳型となる終濃度10ng/μLのHL60 total RNA(タカラバイオ社製)に、実験方法(3)、(4)、(5)で調製したBca、Aac並びにTaq DNAポリメラーゼ変異体精製溶液0.5 ul反応液を加えた、逆転写反応液10μLをそれぞれ調製した。対照として、野生型のBca、Aac並びにTaq DNAポリメラーゼを含む反応液もそれぞれ調製した。
評価試験1は、上記(3)、(4)、(5)で得られたBca、Aac並びにTaq DNAポリメラーゼ変異体について、上記実験方法(6)記載の方法で実施した。その結果を表5に示す。なお、各DNAポリメラーゼ変異体b13b46は、Tth DNAポリメラーゼ変異体b13b46における「Q682R+E689R」変異に対応する変異を有するもの(すなわち、Tth DNAポリメラーゼのアミノ酸配列における682位および689位に対応する位置のアミノ酸がそれぞれアルギニンに置換したもの)である。
上記(3)、(4)、(5)で得られたBca、Aac並びにTaq DNAポリメラーゼ変異体について、cDNAの合成量を確認し逆転写活性を評価した。
SEQ ID NO: 2: PCR forward Primer lambda RNA
SEQ ID NO: 3: PCR Reverse Primer lambda RNA
SEQ ID NO: 4: Probe lambda RNA. 5’-end is labeled FAM and 3’-end is labeled BHQ1
SEQ ID NO: 5: DNA polymerase variant Tth b13
SEQ ID NO: 6: DNA polymerase variant Tth b13
SEQ ID NO: 7: DNA polymerase variant Tth b46
SEQ ID NO: 8: DNA polymerase variant Tth b46
SEQ ID NO: 9: DNA polymerase variant Tth b13 b46
SEQ ID NO: 10: DNA polymerase variant Tth b13 b46
SEQ ID NO: 11: PIP-L14-PIP-L14-PIP-L15 Tth
SEQ ID NO: 12: PCR forward Primer COG1F
SEQ ID NO: 13: PCR Reverse Primer COG1R
SEQ ID NO: 14: PCR forward Primer COG2F
SEQ ID NO: 15: PCR Reverse Primer COG2R
SEQ ID NO: 16: Probe RING1-TP(a). 5’-end is labeled Cy5 and 3’-end is labeled BHQ3
SEQ ID NO: 17: Probe RING2AL-TP. 5’-end is labeled ROX and 3’-end is labeled BHQ2
SEQ ID NO: 18: A partial sequence (A1-A12) of Tth DNA polymerase
SEQ ID NO: 19: A partial sequence (A1-A12) of Tth DNA polymerase variant
SEQ ID NO: 20: A partial sequence (A1-A12) of Bca polymerase
SEQ ID NO: 21: A partial sequence (A1-A12) of Bst polymerase
SEQ ID NO: 22: A partial sequence (A1-A12) of Aac polymerase
SEQ ID NO: 23:DNA polymerase I Bacillus caldotenax
SEQ ID NO: 24:DNA polymerase I Alicyclobacillus acidocaldarius
SEQ ID NO: 25:DNA polymerase I Thermus aquaticus
SEQ ID NO: 26:PCR forward Primer hACTB-F
SEQ ID NO: 27:PCR Reverse Primer hACTB-533
Claims (10)
- A1~A12の12アミノ酸からなる配列を含む、逆転写酵素活性を有するDNAポリメラーゼの変異体であって、ここで
A1は、分枝鎖アミノ酸残基であり;
A2は、親水性の中性アミノ酸残基あるいは疎水性の脂肪族アミノ酸残基であり;
A3は、親水性の中性アミノ酸残基であり;
A4は、酸性アミノ酸残基あるいは親水性の中性アミノ酸残基であり;
A5は、分枝鎖アミノ酸残基であり;
A6は、疎水性の脂肪族アミノ酸残基あるいは親水性の中性アミノ酸残基であり、
A7は、分枝鎖アミノ酸残基であり;
A8は、プロリン残基あるいは親水性の中性アミノ酸残基であり;
A9は、疎水性の芳香族アミノ酸残基、塩基性アミノ酸残基あるいは親水性の中性アミノ酸残基であり;
A10は、酸性アミノ酸残基あるいは塩基性アミノ酸残基であり;
A11は、酸性アミノ酸残基であり;
A12は、疎水性の脂肪族アミノ酸残基であり;及び
前記のA3及び/又はA10のアミノ酸が変異導入前のものとは別の塩基性アミノ酸残基に置換されていることを特徴とする、逆転写酵素活性を有するDNAポリメラーゼ変異体。 - 変異導入前の12アミノ酸からなる配列の、A1がロイシン、A3がグルタミン、A5がロイシン、A7がイソロイシン、A11がグルタミン酸及びA12がアラニンである、請求項1記載の逆転写酵素活性を有するDNAポリメラーゼ変異体。
- 12アミノ酸からなる配列のA3及び/又はA10のアミノ酸がリシン、アルギニン及びヒスチジンからなる群より選択されるアミノ酸に置換されている、請求項1又は2記載の逆転写酵素活性を有するDNAポリメラーゼ変異体。
- サーマス・サーモフィルス由来DNAポリメラーゼ、サーマス・アクアティカス由来DNAポリメラーゼ、バチルス・カルドテナックス由来DNAポリメラーゼ、バチルス・ステアロサーモフィラス由来DNAポリメラーゼあるいはアリシクロバチラス・アシッドカルダリウス由来DNAポリメラーゼの変異体である請求項1~3のいずれか1項に記載の変異体。
- 請求項1~4のいずれかに記載の逆転写酵素活性を有するDNAポリメラーゼ変異体を含むキット。
- 請求項1~4のいずれかに記載の逆転写酵素活性を有するDNAポリメラーゼ変異体を含む組成物。
- RNAからの核酸増幅に適した逆転写酵素活性を有するDNAポリメラーゼの製造方法であって、
(1)A1~A12の12アミノ酸からなる配列を含むDNAポリメラーゼを選択する工程;
A1は、分枝鎖アミノ酸残基であり;
A2は、親水性の中性アミノ酸残基あるいは疎水性の脂肪族アミノ酸残基であり;
A3は、親水性の中性アミノ酸残基であり;
A4は、酸性アミノ酸残基あるいは親水性の中性アミノ酸残基であり;
A5は、分枝鎖アミノ酸残基であり;
A6は、疎水性の脂肪族アミノ酸残基あるいは親水性の中性アミノ酸残基であり、
A7は、分枝鎖アミノ酸残基であり;
A8は、プロリン残基あるいは親水性の中性アミノ酸残基であり;
A9は、疎水性の芳香族アミノ酸残基、塩基性アミノ酸残基あるいは親水性の中性アミノ酸残基であり;
A10は、酸性アミノ酸残基あるいは塩基性アミノ酸残基であり;
A11は、酸性アミノ酸残基であり;
A12は、疎水性の脂肪族アミノ酸残基であり;及び
(2)工程(1)で選択されたDNAポリメラーゼの、上記12アミノ酸からなる配列におけるA3及び/又はA10のアミノ酸が変異導入前のものとは別の塩基性アミノ酸残基に置換する工程、を含む方法。 - 工程(1)において、12アミノ酸からなる配列において、A1がロイシン、A3がグルタミン、A5がロイシン、A7がイソロイシン、A11がグルタミン酸及びA12がアラニンであるDNAポリメラーゼを選択する、請求項7記載の製造方法。
- 工程(2)において、A3及び/又はA10がリシン、アルギニン及びヒスチジンからなる群より選択されるアミノ酸に置換されることを特徴とする、請求項7又は8記載の製造方法。
- 逆転写酵素活性を有するDNAポリメラーゼの改良方法であって、以下のA1~A12に示す12アミノ酸からなる配列を含む、逆転写酵素活性を有するDNAポリメラーゼにおいて、A3及び/又はA10のアミノ酸を別の塩基性アミノ酸残基に置換することを特徴とする方法:
A1は、分枝鎖アミノ酸残基であり;
A2は、親水性の中性アミノ酸残基あるいは疎水性の脂肪族アミノ酸残基であり;
A3は、親水性の中性アミノ酸残基であり;
A4は、酸性アミノ酸残基あるいは親水性の中性アミノ酸残基であり;
A5は、分枝鎖アミノ酸残基であり;
A6は、疎水性の脂肪族アミノ酸残基あるいは親水性の中性アミノ酸残基であり、
A7は、分枝鎖アミノ酸残基であり;
A8は、プロリン残基あるいは親水性の中性アミノ酸残基であり;
A9は、疎水性の芳香族アミノ酸残基、塩基性アミノ酸残基あるいは親水性の中性アミノ酸残基であり;
A10は、酸性アミノ酸残基あるいは塩基性アミノ酸残基であり;
A11は、酸性アミノ酸残基であり;及び
A12は、疎水性の脂肪族アミノ酸残基である。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020530136A JP7324200B2 (ja) | 2018-07-13 | 2019-07-03 | Rnaからの核酸増幅反応に適したdnaポリメラーゼ変異体 |
US17/257,986 US12018294B2 (en) | 2018-07-13 | 2019-07-03 | DNA polymerase mutant suited to nucleic acid amplification from RNA |
EP19833322.1A EP3822349A4 (en) | 2018-07-13 | 2019-07-03 | DNA POLYMERASE MUTATION SUITABLE FOR NUCLEIC ACID AMPLIFICATION FROM RNA |
CN201980046835.1A CN112513262A (zh) | 2018-07-13 | 2019-07-03 | 适合于从rna进行核酸扩增的dna聚合酶突变体 |
KR1020217002014A KR20210031699A (ko) | 2018-07-13 | 2019-07-03 | Rna로부터의 핵산 증폭반응에 적합한 dna 폴리머라아제 돌연변이체 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018-133086 | 2018-07-13 | ||
JP2018133086 | 2018-07-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020013058A1 true WO2020013058A1 (ja) | 2020-01-16 |
Family
ID=69142423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/026513 WO2020013058A1 (ja) | 2018-07-13 | 2019-07-03 | Rnaからの核酸増幅反応に適したdnaポリメラーゼ変異体 |
Country Status (6)
Country | Link |
---|---|
US (1) | US12018294B2 (ja) |
EP (1) | EP3822349A4 (ja) |
JP (1) | JP7324200B2 (ja) |
KR (1) | KR20210031699A (ja) |
CN (1) | CN112513262A (ja) |
WO (1) | WO2020013058A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113186175B (zh) * | 2021-06-04 | 2023-08-04 | 翌圣生物科技(上海)股份有限公司 | 突变型Taq DNA聚合酶、编码DNA序列、重组载体、重组表达细胞及其应用 |
CN113817708B (zh) * | 2021-11-23 | 2022-02-18 | 中国医学科学院北京协和医院 | 一种重组dna聚合酶及其制备方法和应用 |
CN114891761B (zh) * | 2022-03-25 | 2024-01-12 | 上海威高医疗技术发展有限公司 | Tth DNA聚合酶突变体及其应用 |
CN116814584A (zh) * | 2022-06-29 | 2023-09-29 | 武汉爱博泰克生物科技有限公司 | 一种Taq DNA聚合酶突变体及其应用 |
CN117210433B (zh) * | 2023-09-27 | 2024-03-19 | 北京默唐生物科技有限责任公司 | 超速高保真兼并逆转录dna聚合酶和基于该酶的基因扩增、逆转录方法以及试剂 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000508538A (ja) * | 1996-04-17 | 2000-07-11 | モレキュラー バイオロジー リソーシーズ,インコーポレイテッド | バシラス ステアロテルモフィルスdnaポリメラーゼの生物学的に活性な断片 |
JP3844975B2 (ja) | 2000-04-18 | 2006-11-15 | エフ.ホフマン−ラ ロシュ アーゲー | 突然変異型dnaポリメラーゼを使用する高温逆転写 |
WO2007004654A1 (ja) | 2005-07-04 | 2007-01-11 | Celestar Lexico-Sciences, Inc. | 変異型pcna |
JP2007520227A (ja) * | 2004-02-05 | 2007-07-26 | ライニッシェ フリードリッヒ ヴィルヘルムス ウニヴェルジテート ボン | 誤対合識別の増加を有する変異dnaポリメラーゼ |
WO2007143436A2 (en) * | 2006-05-30 | 2007-12-13 | Ge Healthcare Bio-Sciences Corp. | Dna polymerase from spirochaeta thermophila |
WO2009054510A1 (ja) * | 2007-10-25 | 2009-04-30 | Riken | 等温増幅方法およびそれに用いるdnaポリメラーゼ |
WO2014090836A1 (en) | 2012-12-13 | 2014-06-19 | Roche Diagnostics Gmbh | Dna polymerases with improved activity |
WO2017090685A1 (ja) | 2015-11-27 | 2017-06-01 | 国立大学法人九州大学 | Dnaポリメラーゼ変異体 |
JP2017178804A (ja) * | 2016-03-29 | 2017-10-05 | 東洋紡株式会社 | 融合タンパク質 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1201768B1 (en) | 2000-10-25 | 2005-12-14 | Roche Diagnostics GmbH | Amplification using modified primers |
CA2831180C (en) * | 2011-04-11 | 2017-02-14 | Keith Bauer | Dna polymerases with improved activity |
GB201113430D0 (en) | 2011-08-03 | 2011-09-21 | Fermentas Uab | DNA polymerases |
WO2013083262A1 (en) * | 2011-12-08 | 2013-06-13 | Roche Diagnostics Gmbh | Dna polymerases with improved activity |
WO2013083264A1 (en) * | 2011-12-08 | 2013-06-13 | Roche Diagnostics Gmbh | Dna polymerases with improved activity |
WO2017090684A1 (ja) * | 2015-11-27 | 2017-06-01 | 国立大学法人九州大学 | Dnaポリメラーゼ変異体 |
JP7363063B2 (ja) * | 2018-03-15 | 2023-10-18 | 東洋紡株式会社 | 変異型dnaポリメラーゼ |
-
2019
- 2019-07-03 US US17/257,986 patent/US12018294B2/en active Active
- 2019-07-03 EP EP19833322.1A patent/EP3822349A4/en active Pending
- 2019-07-03 WO PCT/JP2019/026513 patent/WO2020013058A1/ja unknown
- 2019-07-03 JP JP2020530136A patent/JP7324200B2/ja active Active
- 2019-07-03 KR KR1020217002014A patent/KR20210031699A/ko active Search and Examination
- 2019-07-03 CN CN201980046835.1A patent/CN112513262A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000508538A (ja) * | 1996-04-17 | 2000-07-11 | モレキュラー バイオロジー リソーシーズ,インコーポレイテッド | バシラス ステアロテルモフィルスdnaポリメラーゼの生物学的に活性な断片 |
JP3844975B2 (ja) | 2000-04-18 | 2006-11-15 | エフ.ホフマン−ラ ロシュ アーゲー | 突然変異型dnaポリメラーゼを使用する高温逆転写 |
JP2007520227A (ja) * | 2004-02-05 | 2007-07-26 | ライニッシェ フリードリッヒ ヴィルヘルムス ウニヴェルジテート ボン | 誤対合識別の増加を有する変異dnaポリメラーゼ |
WO2007004654A1 (ja) | 2005-07-04 | 2007-01-11 | Celestar Lexico-Sciences, Inc. | 変異型pcna |
WO2007143436A2 (en) * | 2006-05-30 | 2007-12-13 | Ge Healthcare Bio-Sciences Corp. | Dna polymerase from spirochaeta thermophila |
WO2009054510A1 (ja) * | 2007-10-25 | 2009-04-30 | Riken | 等温増幅方法およびそれに用いるdnaポリメラーゼ |
WO2014090836A1 (en) | 2012-12-13 | 2014-06-19 | Roche Diagnostics Gmbh | Dna polymerases with improved activity |
WO2017090685A1 (ja) | 2015-11-27 | 2017-06-01 | 国立大学法人九州大学 | Dnaポリメラーゼ変異体 |
JP2017178804A (ja) * | 2016-03-29 | 2017-10-05 | 東洋紡株式会社 | 融合タンパク質 |
Non-Patent Citations (6)
Title |
---|
"NCBI", Database accession no. WP_011228405.1 |
"The detection method of norovirus", 5 November 2003, INSPECTION AND SAFETY DIVISION, FOOD SAFETY DEPARTMENT, PHARMACEUTICAL AND FOOD SAFETY BUREAU |
AYE, S. L. ET AL.: "Engineering of DNA polymerase I from Thermus thermophilus using compartmentalized self-replication", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 499, no. 9, 21 March 2018 (2018-03-21), pages 170 - 176, XP055674591 * |
LOH, E. ET AL.: "Mutability of DNA polymerase I: Implications for the creation of mutant DNA polymerases", DNA REPAIR, vol. 4, no. 12, 2005, pages 1390 - 1398, XP005171271, DOI: 10.1016/j.dnarep.2005.09.006 * |
See also references of EP3822349A4 |
SIMON, C. ET AL.: "Rapid Identification of Genes Encoding DNA Polymerases by Function-Based Screening of Metagenomic Libraries Derived from Glacial Ice", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 75, no. 9, 2009, pages 2964 - 2968, XP055674594 * |
Also Published As
Publication number | Publication date |
---|---|
US12018294B2 (en) | 2024-06-25 |
EP3822349A4 (en) | 2022-04-06 |
US20210222137A1 (en) | 2021-07-22 |
CN112513262A (zh) | 2021-03-16 |
JP7324200B2 (ja) | 2023-08-09 |
EP3822349A1 (en) | 2021-05-19 |
KR20210031699A (ko) | 2021-03-22 |
JPWO2020013058A1 (ja) | 2021-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7324200B2 (ja) | Rnaからの核酸増幅反応に適したdnaポリメラーゼ変異体 | |
CN110291196B (zh) | 耐热逆转录酶突变体 | |
US10597644B2 (en) | DNA polymerases with improved activity | |
JP6224613B2 (ja) | 改善された活性を有するdnaポリメラーゼ | |
JP6140182B2 (ja) | 改善された活性を有するdnaポリメラーゼ | |
WO2014090836A1 (en) | Dna polymerases with improved activity | |
JP2003510052A (ja) | 改良されたポリヌクレオチド合成のための方法と組成物 | |
JP6378085B2 (ja) | 改善された活性を有するdnaポリメラーゼ | |
JP2023541511A (ja) | 活性および熱安定性が向上した逆転写酵素変異体 | |
AU2011267421B2 (en) | DNA polymerases with increased 3'-mismatch discrimination | |
JP7363063B2 (ja) | 変異型dnaポリメラーゼ | |
JP2020182463A (ja) | 核酸増幅試薬 | |
JP2015050994A (ja) | 核酸増幅法 | |
JP2022500046A (ja) | 改善されたストランド置換能力を有する変異体dnaポリメラーゼ | |
KR101230362B1 (ko) | 나노아케움 이퀴탄스 dna 중합효소의 단백질 트랜스 스플라이싱을 기반으로 한 핫―스타트 pcr 수행방법 | |
WO2019180137A1 (en) | Dna polymerases for efficient and effective incorporation of methylated-dntps | |
JPWO2016104272A1 (ja) | Pcr方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19833322 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020530136 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20217002014 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019833322 Country of ref document: EP Effective date: 20210215 |